EMA will review a marketing authorization application for Masitinib in the treatment of Imatinib resistant GIST

PRESS RELEASE

07. October 2012


EMA will review a marketing authorization application for Masitinib in the treatment of Imatinib resistant GIST

The pharmaceutical company AB Science SA announced on the 4th of October 2012 that the European Medicines Agency (EMA) has accepted for review a Marketing Authorization Application (MAA) for Masitinib in the treatment of patients with Imatinib-(Glivec®)-resistant GIST.

 

Filing for the Marketing Authorization of Masitinib in GIST resistant to Imatinib was accepted by EMA on the basis of results from a phase II study that showed Masitinib to improve overall survival in patients with Imatinib-resistant GIST as compared with Sunitinib (Sutent®), which is currently the standard of care for second-line treatment of GIST. In this study, 44 patients with inoperable, locally advanced or metastatic GIST and showing disease progression while treated with Imatinib (400 to 800 mg/day) received either Masitinib (23 patients) at 12 mg/kg/day or Sunitinib (21 patients) at 50 mg/day until progression. After a median follow-up of 17 months, the median overall survival was not reached for Masitinib versus 16 months for Sunitinib (hazard ratio:0.27 - 95% CI [0.09)(hazard ratio:0.78]). The Overall Survival rate estimates at 6, 12, and 18 months were respectively, 95.7%, 81.9%, and 81.9% in Masitinib-treated patients, versus 76.2%, 57.1%, and 42.3% in Sunitinib-treated patients. Masitinib was well tolerated, with 17% of patients reporting non-hematological grade 3 related adverse events, as compared with 62% of patients in the Sunitinib treatment arm. No patients receiving Masitinib reported any related serious adverse events compared with 19% of patients in the Sunitinib treatment arm.

Masitinib is an orally administered tyrosine kinase inhibitor that targets mast cells, important cells for immunity, as well as a limited number of kinases that play key roles in various cancers. Masitinib, has already been registered in veterinary medicine in Europe and in the USA, and is pursuing different studies in human medicine - including on-going studies in GIST. Masitinib is still an investigational agent and currently not approved by EMA, FDA or other health authorities. Please remember: An approval of an application means that a review for a potential Marketing Authorization will be done. This means not - that the approval of the application is guaranteed.


ABOUT SPAEN

The European Network of Sarcoma Patient Advocacy Groups

European GIST, Desmoid and Sarcoma advocacy and support groups have agreed to form the collaborative association Sarcoma Patients EuroNet. SPAEN was officially founded on the 6th of April 2009 in Bad Nauheim/Germany. SPAEN is an European association – legally registered under German law. The association has some short term goals and some long term ambitions, and is supporting the growing pressure for better treatment of rare cancers being led by groups such as RARECARE, EURORDIS, ESMO and ECPC. The organization has already started its work with the aim of extending information services, patient support and advocacy so that patients across the whole of Europe can benefit. Acting in partnership with experts, the healthcare industry and other stakeholders, SPAEN will work to improve treatment and care of GIST, Desmoid and sarcoma patients in Europe through improving information and support, and by increasing the visibility of sarcoma with policymakers and the public.



CONTACT

Roger Wilson (SPAEN President)

E-Mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Estelle Lecointe (SPAEN Vice-President)
E-Mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Markus Wartenberg (SPAEN Financial Director)

E-Mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Barbara Dore (SPAEN Secretary)
E-Mail: This email address is being protected from spambots. You need JavaScript enabled to view it.


SPAEN Secretariat

Michaela Geissler (Senior Project Manager)

E-Mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Member LogIn